A Randomized Controlled Trial of Personalized Text Message Reminders to Promote Medication Adherence Among HIV-Positive Adolescents and Young Adults

AIDS and Behavior

Volumn 20, Issue 5, 2016, Pages 1049-1059

  Garofalo, Robert ^a,b   Kuhns, Lisa M ^a,b   Hotton, Anna ^c   Johnson, Amy ^a,d   Muldoon, Abigail ^a   Rice, Dion ^a  

^a CHILDREN'S MEMORIAL HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Jr Hospital of Cook County   (United States)

^d AIDS FOUNDATION OF CHICAGO   (United States)

Author keywords

HIV infection; Medication adherence; Text messaging; Youth

Indexed keywords

ADOLESCENT; ADULT; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN; MALE; MEDICATION COMPLIANCE; MOTIVATION; OUTCOME ASSESSMENT; PAIN MEASUREMENT; PATIENT ATTITUDE; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; REMINDER SYSTEM; SELF CONCEPT; TEXT MESSAGING; TREATMENT OUTCOME; UTILIZATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; MOTIVATION; OUTCOME ASSESSMENT (HEALTH CARE); PAIN MEASUREMENT; PATIENT ACCEPTANCE OF HEALTH CARE; REMINDER SYSTEMS; SELF EFFICACY; TEXT MESSAGING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84941343441     PISSN: 10907165     EISSN: 15733254     Source Type: Journal    
DOI: 10.1007/s10461-015-1192-x     Document Type: Article

References (48)

1. Centers for Disease Control and Prevention. HIV surveillance report, 2013. Atlanta: GA; 2013.
2. Centers for Disease Control and Prevention. HIV surveillance report, 2011. Atlanta: GA; 2013.
3. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–97.
4. Bangsberg. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43(7):939–41.
5. Parienti JJ, Das-Douglas M, Massari V, Guzman D, Deeks SG, Verdon R, et al. Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PloS one. 2008;3(7):e2783–7.
6. Feingold A, Rutstein R, Meislich D, Brown T, Rudy B. Protease inhibitor therapy in HIV-infected children. AIDS Patient Care STDS. 2000;14(11):589–93.
7. Flynn P, Rudy B, Douglas S, et al. Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy. J| Infect Dis. 2004;190(2):271–9.
8. Gross R, Bilker WB, Friedman HM, Strom BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS. 2001;15(16):2109–17.
9. Lafeuillade A, Tamalet C, Pellegrino P, De Micco P, Vignoli C, Quilichini R. Correlation between surrogate markers, viral load, and disease progression in HIV-1 infection. J Acquir Immune Defic Syndr. 1994;7(10):1028–33.
10. McNabb J, Ross J, Abriola K, Turley C, Nightingale C, Nicolau D. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clin Infect Dis. 2001;33(5):700–5.
11. Murphy D, Wilson C, Durako S, Muenz L, Belzer M. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care. 2001;13(1):27–40.
12. Paterson D, Swindells S, Mohr J, Brester M, Vergis E, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30.
13. Rao D, Kekwaletswe T, Hosek S, Martinez J, Rodriguez F. Stigma and social barriers to medication adherence with urban youth living with HIV. AIDS Care. 2007;19(1):28–33.
14. Belzer M, Fuchs DN, Luftman GS, Tucker DJ. Antiretroviral adherence issues among HIV-positive adolescents and young adults. J Adolesc Health. 1999;25:316–9.
15. Comulada W, Swendeman D, Rotheram-Borus M, Mattes K, Weiss R. Young people living with HIV. Am J Health Behav. 2003;27(4):389–400.
16. Martinez J, Bell D, Camacho R, Henry-Reid LM, Bell M, Watson C, et al. Adherence to antiviral drug regimens in HIV-infected adolescent patients engaged in care in a comprehensive adolescent and young adult clinic. J Natl Med Assoc. 2000;92(2):55–61.
17. M urphy D, Belzer M, Durako S, Moussa S, Wilson C, Muenz L. Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virus. Arch Pediatr Adolesc Med. 2005;159(8):764–70.
18. Naar-King S, Templin T, Wright K, Frey M, Parsons J, Lam P. Psychosocial factors and medication adherence in HIV-positive youth. AIDS Patient Care STDs. 2006;20(1):44–7.
19. Rogers AS, Miller S, Murphy D, Tanney M, Fortune T. The TREAT (therapeutic regimens enhancing adherence in teens) program: theory and preliminary results. J Adolesc Health. 2001;29S:30–8.
20. Murphy DA, Sarr M, Durako SJ, Moscicki AB, Wilson CM, Muenz LR. Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med. 2003;157(3):249–55.
21. Reisner SL, Mimiaga MJ, Skeer M, Perkovich B, Johnson CV, Safren SA. A review of HIV antiretroviral adherence and intervention studies among HIV-infected youth. Top HIV Med. 2009;17(1):14–25.
22. MacDonell K, Naar-King S, Huszti H, Belzer M. Barriers to medication adherence in behaviorally and perinatally infected youth living with HIV. AIDS Behav. 2013;17(1):86–93.
23. Woods S, Dawson MS, Weber E, Gibson S, Grant I, Atkinson JH. HIV Neurobehavioral Research Center Group, timing is everything: antiretroviral nonadherence is associated with impairment in time-based prospective memory. J Int Neuropsychol Soc. 2009;15:42–52.
24. Fjeldsoe BS, Marshall AL, Miller YD. Behavior change interventions delivered by mobile telephone short-message service. Am J Prev Med. 2009;36(2):165–73.
25. Pew Research Center. Mobile technology fact sheet. Washington, DC: Pew Internet and American Life Project; 2014.
26. Pew Research Center. Teens and technology. Washington, DC: Pew Research Center; 2013.
27. Finitsis DJ, Pellowski JA, Johnson BT. Text message intervention designs to promote adherence to antiretroviral therapy (ART): a meta-analysis of randomized controlled trials. PLoS ONE. 2014;9(2):e88166.
28. Horvath T, Azman H, Kennedy GE, Rutherford GW. Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection. Cochrane Database Syst Rev. 2012;3:CD009756.
29. Mbuagbaw L, van der Kop ML, Lester RT, Thirumurthy H, Pop-Eleches C, Ye C, et al. Mobile phone text messages for improving adherence to antiretroviral therapy (ART): an individual patient data meta-analysis of randomised trials. BMJ open. 2013;3(12):e003950.
30. Dowshen N, Kuhns LM, Johnson A, Holoyda BJ, Garofalo R. Improving adherence to antiretroviral therapy for youth living with HIV/AIDS: a pilot study using personalized, interactive, daily text message reminders. J Med Internet Res. 2012;14(2):e51.
31. Bandura A. The anatomy of stages of change. Am J Health Promot. 1997;12:8–10.
32. Bandura A. Health promotion by social cognitive means. Health Educ Behav. 2004;31:143–64.
33. Macdonell K, Naar-King S, Murphy DA, Parsons JT, Harper GW. Predictors of medication adherence in high risk youth of color living with HIV. J Pediatr Psychol. 2010;35(6):593–601.
34. BioCreations. HIV drug resistance and the importance of adherence. Johns Hopkins School of Medicine Division of Infectious Diseases; 2008.
35. Dowshen N, Kuhns LM, Gray C, Lee S, Garofalo R. Feasibility of interactive text message response (ITR) as a novel, real-time measure of adherence to antiretroviral therapy for HIV+ Youth. AIDS Behav. 2013;17(6):2237–43.
36. Belzer ME, Naar-King S, Olson J, Sarr M, Thornton S, Kahana SY, et al. The use of cell phone support for non-adherent HIV-infected youth and young adults: an initial randomized and controlled intervention trial. AIDS Behav. 2014;18(4):686–96.
37. Erlen JA, Cha ES, Kim KH, Caruthers D, Sereika SM. The HIV medication taking self-efficacy scale: psychometric evaluation. J Adv Nurs. 2010;66(11):2560–72.
38. Tucker CM, Peterson S, Herman KC, Fennell RS, et al. Self-regulation predictors of medication adherence among ethnically different pediatric patients with renal transplants. J Pediatr Psychol. 2001;26(8):455–64.
39. Wright K, Naar-King S, Lam P, Templin T, Frey M. Stigma scale revised: reliability and validity of a brief measure of stigma for HIV+ youth. J Adolesc Health. 2007;40(1):96–8.
40. Derogatis L. Brief symptom inventory: administration, scoring, and procedures manual. Minneapolis, MN: National Computer Systems, Inc.; 1993.
41. Humeniuk R. Validation of the alcohol, smoking and substance involvement screening test (ASSIST) and pilot brief intervention: a technical report of phase II findings of the WHO ASSIST project. Geneva: World Health Organization; 2006.
42. Larsen DL, Attkisson CC, Hargreaves WA, Nguyen TD. Assessment of client/patient satisfaction: development of a general scale. Eval Progr Plan. 1979;2:197–207.
43. MacKinnon DP, Lockwood CM, Hoffman JM, West SG, Sheets V. A comparison of methods to test mediation and other intervening variable effects. Psychol Methods. 2002;7(1):83–104.
44. MacKinnon DP, Fairchild AJ, Fritz MS. Mediation analysis. Annu Rev Psychol. 2007;58:593–614.
45. Preacher KJ, Hayes AF. Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behav Res Methods. 2008;40(3):879–91.
46. Selig JP, Preacher KJ. Mediation models for longitudinal data in developmental research. Res Hum Dev. 2009;6:144–64.
47. Simoni JM, Pearson CR, Pantalone DW, Marks G, Crepaz N. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trials. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S23–35.
48. Bain-Brickley D, Butler LM, Kennedy GE, Rutherford GW. Interventions to improve adherence to antiretroviral therapy in children with HIV infection. Cochrane Database of System Rev. 2011;12:CD009513.